Shruti Gupta, MD, MPH

Shruti Gupta MD, MPH is an Assistant Professor of Medicine at Harvard Medical School and Director of Onconephrology at Brigham and Women’s Hospital/Dana-Farber Cancer Institute (DFCI). Dr. Gupta conducts epidemiologic, translational, and interventional studies related to the nephrotoxic effects of cancer therapies. She is funded by an NIH K23 award examining therapeutic targets for cisplatin-associated acute kidney injury (AKI), along with several investigator-initiated industry-funded studies. She is co-principal investigator of an international multicenter study examining outcomes among patients with immune checkpoint inhibitor-associated AKI (ICPi-AKI); her first-author publication on clinical features and outcomes of ICPi-AKI was selected as Clinical/Translational Paper of the Year by the Journal of Immunotherapy Cancer in 2022. She was also selected as recipient of the prestigious Wong award at DFCI to conduct translational research related to ICPi-AKI. In addition, she is principal investigator of multicenter studies related to methotrexate-associated AKI and myeloma light chain cast nephropathy. She has gained international renown, having given invited presentations in Brazil, Peru, Switzerland, India, and China. She is on the steering committee for the next ADQI consensus conference on onconephrology. In 2021, Shruti founded the American Society of Onconephrology, which now has >150 members across 14 countries, and served as the first president of the organization.